With $845m raised to date, ElevateBio will keep building its cell and gene therapy manufacturing capabilities and continue creating new companies and partnerships, but with a global focus.

Two US VCs have led a large $75m series B financing of Belgium’s AgomAb Therapeutics, which is gaining traction in developing antibodies that act on the HGF-MET pathway, potentially reversing fibrosis and allowing damaged tissues to regain function.

In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.

The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.